Attempting a new post series called Daily Effort: a dense expression of an Open Lifespan/Open Healthspan related idea (question, argument, proposal …) in a couple of sentences. Without context or tight, detailed argumentation. Consider these as drafts, some of them will be elaborated upon, some of them will be revoked if don’t stand up to scrutiny. In any case, these are my drafts here am working on, reaching a stage where it might be interesting for others too. Let’s go.
Today’s idea is simple and I phrase it as a question (and a bundle of follow-up questions), rather than a proposal as originally intended: if a drug has reported and potential lifespan and/or healthspan lengthening benefits, should this information be printed on the label too amongst potential side effects? Think of metformin here as a prime example where observational evidence suggests longer survival time for metformin user diabetics compared to non-diabetic, non-users. Generally speaking: should positive, lifespan prolonging side effects should be highlighted for users just as much as negative or adversarial life effects? The term pharmacovigilance is generally known as drug safety with a focus on negative or adverse effects, but not so much on the potential extra benefits of medicines. So I suggest a new term, pharmacodiligence which should involve highlighting potential positive side effects too like lifespan lengthening. Should patients know? Is this the same question as asking off-label use to be put on-label?
I plan to work out some details here later, as time allows or discussion necessitates.